ICMR to conduct trials of indigenously developed Zika vaccine
The Economics Times
Nov. 18, 2018
Reference: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/icmr-to-conduct-trials-of-indigenously-developed-zika-vaccine/articleshow/66677823.cms
Nov. 18, 2018
NEW
DELHI: The Indian Council of Medical Research (ICMR) will soon undertake trials
of the indigenously developed vaccine against Zika virus, cases of which have
been reported in Madhya Pradesh, Rajasthan and Gujarat.
The
ICMR will undertake phase-II trial of the vaccine to establish the efficacy and
safety of the vaccine along with its adverse effects, a senior official
said.
Vaccines
manufacturer, Hyderabad-based Bharat Biotech, has developed a vaccine, which
they claim will provide protection against infection caused by an Asian Zika
virus strain as well as by the African Zika virus strain, the official
said.
"The
company had developed the vaccine around two years ago. At that time we did not
have an outbreak of Zika in India as it was only restricted to Latin America.
Â
"Zika
virus is spread to people primarily through the bite of an infected Aedes
species mosquito and also there is a breakout in some states. Vector control is
one of the most challenging work. Thus the vaccine, if its efficacy is proved,
is a better strategy," the official said.
The
process for regulatory approvals to carry out the trial will be initiated soon,
he informed.
Two
persons, who tested positive for the Zika virus, died in Madhya Pradesh's
Bhopal district while the number of people suffering from the disease has
crossed 120 in the state.
The
deceased -- an 18-year-old man and a 23-year-old woman -- were suffering from
the virus and other "serious" diseases. Therefore, it cannot be said
they died due to Zika , officials had clarified.
The
virus has infected 127 people, out of which 40 are pregnant women, the
officials said.
People
have tested positive for the Zika virus in seven districts of Madhya Pradesh.
This includes 44 cases reported from Bhopal, 20 from Sehore, 29 from Vidisha,
two each from Sagar and Hoshangabad, and one each from Narsinghpur and
Raisen.
A
central team is reviewing the situation and assisting the Madhya Pradesh
government to replicate measures and the action plan implemented in Jaipur and
Ahmedabad to contain the disease, the senior official said.
Rajasthan
has reported 159 cases of Zika infections.
In
India, the first outbreak of the Zika virus was reported in Ahmedabad in
January 2017 and the second in Tamil Nadu's Krishnagiri district in July that
year. Both these outbreaks were successfully contained through intensive
surveillance and vector management.
During
the latest outbreak of the virus in the country, the first case surfaced on
September 22, when an 85-year-old woman tested positive for the virus in
Jaipur. Since then, the number of Zika cases have risen to 153 in
Rajasthan.
In
Madhya Pradesh an intensive screening exercise is being undertaken and vector
control measures have been intensified. The government has also issued an
advisory to district administrations to take steps to check mosquito
breeding.
The state health department has
advised pregnant women not to visit the affected areas.
The Zika virus, transmitted through the aedes aegypti mosquito, causes fever, skin rashes, conjunctivitis, muscle and joint pain.
The Zika virus, transmitted through the aedes aegypti mosquito, causes fever, skin rashes, conjunctivitis, muscle and joint pain.
It
is harmful for pregnant women, as the mother can pass the infection to her
fetus during pregnancy or around the time of birth leading to microcephaly, a
condition in which a baby's head is significantly smaller than normal.
The
disease is under surveillance of the Union Health Ministry although it is no
longer a Public Health Emergency of International Concern under the WHO
notification. Reference: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/icmr-to-conduct-trials-of-indigenously-developed-zika-vaccine/articleshow/66677823.cms
Comments
Post a Comment